SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Evel Knievel Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEvel Knievel
Date of birth1938-10-17
IdentifiersMRN HR-RB001-SYN-TD; SSN (made up) 000-01-4927
Document date2026-11-01
AuthorDale Rasmussen, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient: chronic pain from old fractures, diabetes, and raised liver tests with low platelets on today's tests: hepatitis C and liver work-up, NSAIDs stopped, alcohol counseling, and hepatology review booked. Concerns: Pain in the back, hips and knees every day from old fractures, worse in the morning and after travel; ibuprofen three times a day for years; Tired for months; noticed small red spots on his chest and wonders whether the old transfusions or his drinking have hurt his liver; He wants to keep walking and playing golf and does not want to depend on strong pain pills; Two falls in the past year; he worries about breaking another bone. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet twice daily with breakfast and supperOral route1991-03-01activeS
Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back painOne tablet three times a dayOral route1994-06-01 to 1996-01-12completedS
Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofenOne capsule daily before breakfastOral route1994-06-01 to 1996-01-12completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a dayTwo tablets up to twice a day as needed; no more than 2 g a dayOral route1996-01-12activeS
Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day4 g to each knee up to four times a dayTopical route1996-01-12activeS
Carvedilol 6.25 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-01-26 to 1996-02-23completedS
Carvedilol 12.5 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-02-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1996-01-26activeS
Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet, one tablet daily for 12 weeksOne tablet daily for 12 weeksOral route1996-02-23 to 1996-05-17completedS
Cholecalciferol (vitamin D3) 50 mcg (1970 units) oral capsule, one capsule dailyOne capsule dailyOral route1996-02-23activeS
Zoledronic acid 5 mg in 100 mL, intravenous infusion over at least 15 minutes, once a yearOnce a yearIntravenous route1996-06-01activeS

Procedures

ProcedureDatesStatusEvidence
Ultrasound of the abdomen with Doppler: nodular liver surface and coarse echotexture; no focal liver lesion; spleen 14.2 cm; portal vein patent with forward flow; no ascites; gallbladder normal1996-01-19 to 1996-01-19completedS
Transient elastography (FibroScan) at the hepatology visit: median liver stiffness 26.8 kPa (interquartile range under 30% of the median), controlled attenuation parameter 248 dB/m1996-01-26 to 1996-01-26completedS
Outpatient physical therapy assessment: limited hip and knee range from old fractures, slow gait, Timed Up and Go 13 seconds, poor single-leg balance; aquatic therapy twice a week and a home exercise program; cane for long distances1996-02-02 to 1996-02-02completedS
Dual-energy X-ray absorptiometry: femoral neck T-score -2.6, total hip -2.2, lumbar spine -1.9 (read with caution because of old fractures and degenerative change); 10-year FRAX risk of major osteoporotic fracture 14% and hip fracture 4.1%1996-03-09 to 1996-03-09completedS
Surveillance ultrasound of the liver six months after the baseline scan: nodular liver, no focal lesion; spleen 13.8 cm; no ascites (LI-RADS US-1, negative)1996-08-10 to 1996-08-10completedS
Advance care planning conversation, about 20 minutes1996-09-21 to 1996-09-21completedS

Immunizations

DateVaccineStatusEvidence
1996-01-26Hepatitis A vaccine, adult, dose 1 of 2completedS
1996-01-26Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 1 of 2completedS
1996-02-23Hepatitis B vaccine (recombinant, CpG adjuvanted), dose 2 of 2completedS
1996-08-17Hepatitis A vaccine, adult, dose 2 of 2completedS
1996-09-21Influenza vaccine, inactivated, trivalent, preservative free, this seasoncompletedS
1996-09-21Pneumococcal conjugate vaccine PCV20completedS
1996-09-21Recombinant zoster vaccine, dose 1 of 2completedS
1996-09-21Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1968Crash after jumping the fountains at Caesars Palace, Las Vegas, with a long hospital stay (reported as a month in a coma)D (CLM-0002)
September 8, 1974Failed rocket-cycle jump of the Snake River Canyon, IdahoD (CLM-0003)
1975Broken pelvis in the crash landing of a jump over 13 buses at Wembley Stadium, London; Guinness World Records counts 433 fractures by the end of that year (disputed; his obituaries say nearly 40 broken bones in his career)D (CLM-0003, CLM-0004)
1976Concussion and two broken arms in a jump attempt in Chicago; retired from major jumpsD (CLM-0003)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
Pain in the back, hips and knees every day from old fractures, worse in the morning and after travel; ibuprofen three times a day for yearsactiveS
Tired for months; noticed small red spots on his chest and wonders whether the old transfusions or his drinking have hurt his liveractiveS
He wants to keep walking and playing golf and does not want to depend on strong pain pillsactiveS
Two falls in the past year; he worries about breaking another boneactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 14.4 on 1996-08-17; Leukocytes [#/volume] in Blood by Automated count 5.2 on 1996-08-17; Platelets [#/volume] in Blood by Automated count 134 on 1996-08-17; Sodium [Moles/volume] in Serum or Plasma 137 on 1996-01-12; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1996-01-12; Creatinine [Mass/volume] in Serum or Plasma 0.88 on 1996-08-17; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1991)/1.73 sq M 100 on 1996-08-17; Glucose [Mass/volume] in Serum or Plasma 112 on 1996-08-17; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 1996-08-17; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 1996-08-17; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 92 on 1996-08-17; Bilirubin.total [Mass/volume] in Serum or Plasma 0.8 on 1996-08-17; Albumin [Mass/volume] in Serum or Plasma 4 on 1996-08-17; INR in Platelet poor plasma by Coagulation assay 1 on 1996-08-17; Hemoglobin A1c/Hemoglobin.total in Blood 6.3 on 1996-08-17; Cholesterol [Mass/volume] in Serum or Plasma 148 on 1996-09-21; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 68 on 1996-09-21; Cholesterol in HDL [Mass/volume] in Serum or Plasma 42 on 1996-09-21; Triglyceride [Mass/volume] in Serum or Plasma 140 on 1996-09-21; Albumin/Creatinine [Mass Ratio] in Urine 18 on 1996-01-12; Total score [AUDIT-C] 0 on 1996-08-17; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1996-09-21; Pain severity - 0-10 verbal numeric rating [Score] - Reported 4 on 1996-08-17; Liver stiffness by US.transient elastography 26.8 on 1996-01-26; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1996-08-17; Calcium [Mass/volume] in Serum or Plasma 9.3 on 1996-05-18; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 1996-05-18; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 388 on 1996-02-23; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 1996-02-23; Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection 0 on 1996-08-17; Glucose management indicator 6.8 on 1996-08-17; Parathyrin.intact [Mass/volume] in Serum or Plasma 48 on 1996-05-18; Testosterone [Mass/volume] in Serum or Plasma 455 on 1996-05-18; Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma 3.4 on 1996-08-17; Prostate specific Ag [Mass/volume] in Serum or Plasma 1.3 on 1996-09-21 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1962 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review orderedresolvedconfirmed R74.01S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation.
Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis Cresolvedconfirmed B18.2S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D).
Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleedingactiveconfirmed K74.69S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant.
Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII)activeconfirmed K76.6S — Synthetic finding at the hepatology consultation.
Type 2 diabetes on metformin, A1c 7.4%activeconfirmed E11.65S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice.
Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioidsactiveconfirmed G89.29S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years.
Osteoporosis in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: femoral neck T-score -2.6, lumbar spine -1.9activeconfirmed M81.8S — Synthetic bone density result.
Vitamin D deficiency (25-hydroxyvitamin D 17 ng/mL)resolvedconfirmed E55.9S — Synthetic finding before the bone density scan.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1996-01-12Hemoglobin [Mass/volume] in Blood13.9g/dL13.5-17.5 g/dLNormalS
1996-01-12Leukocytes [#/volume] in Blood by Automated count4.610*3/uL4-11 10*3/uLNormalS
1996-01-12Platelets [#/volume] in Blood by Automated count11810*3/uL150-400 10*3/uLLowS
1996-01-12Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1996-01-12Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1996-01-12Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.74-1.35 mg/dLNormalS
1996-01-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1991)/1.73 sq M97mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1996-01-12Glucose [Mass/volume] in Serum or Plasma162mg/dL70-99 mg/dLHighS
1996-01-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma88U/L7-55 U/LHighS
1996-01-12Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma96U/L8-48 U/LHighS
1996-01-12Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma104U/L40-129 U/LNormalS
1996-01-12Bilirubin.total [Mass/volume] in Serum or Plasma1.1mg/dL0.1-1.2 mg/dLNormalS
1996-01-12Albumin [Mass/volume] in Serum or Plasma3.6g/dL3.5-5 g/dLNormalS
1996-01-12INR in Platelet poor plasma by Coagulation assay1.1{INR}0.9-1.1NormalS
1996-01-12Hemoglobin A1c/Hemoglobin.total in Blood7.4%Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosisHighS
1996-01-12Cholesterol [Mass/volume] in Serum or Plasma186mg/dL<=199 mg/dLNormalS
1996-01-12Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation112mg/dLGoal below 100 mg/dL in diabetes, below 70 if higher riskHighS
1996-01-12Cholesterol in HDL [Mass/volume] in Serum or Plasma38mg/dL>=40 mg/dLLowS
1996-01-12Triglyceride [Mass/volume] in Serum or Plasma178mg/dL<=149 mg/dLHighS
1996-01-12Albumin/Creatinine [Mass Ratio] in Urine18mg/g<=29 mg/gNormalS
1996-01-12Total score [AUDIT-C]7{score}S
1996-01-12Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1996-01-12Pain severity - 0-10 verbal numeric rating [Score] - Reported7{score}S
1996-01-26Liver stiffness by US.transient elastography26.8kPaBelow 7 kPa normal; above 12.5 kPa cirrhosis; 25 kPa or more clinically significant portal hypertensionHighS
1996-01-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1996-01-26Total score [AUDIT-C]4{score}S
1996-01-26Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S
1996-02-23Hemoglobin [Mass/volume] in Blood14g/dL13.5-17.5 g/dLNormalS
1996-02-23Leukocytes [#/volume] in Blood by Automated count4.810*3/uL4-11 10*3/uLNormalS
1996-02-23Platelets [#/volume] in Blood by Automated count12110*3/uL150-400 10*3/uLLowS
1996-02-23Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.74-1.35 mg/dLNormalS
1996-02-23Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1991)/1.73 sq M100mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1996-02-23Glucose [Mass/volume] in Serum or Plasma141mg/dL70-99 mg/dLHighS
1996-02-23Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma81U/L7-55 U/LHighS
1996-02-23Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma90U/L8-48 U/LHighS
1996-02-23Bilirubin.total [Mass/volume] in Serum or Plasma1mg/dL0.1-1.2 mg/dLNormalS
1996-02-23Albumin [Mass/volume] in Serum or Plasma3.7g/dL3.5-5 g/dLNormalS
1996-02-23Calcium [Mass/volume] in Serum or Plasma9.1mg/dL8.6-10.3 mg/dLNormalS
1996-02-2325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma17ng/mL30-100 ng/mLLowS
1996-02-23Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma388pg/mL232-1245 pg/mLNormalS
1996-02-23Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.4-4.5 mIU/LNormalS
1996-02-23Total score [AUDIT-C]1{score}S
1996-02-23Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1996-02-23Pain severity - 0-10 verbal numeric rating [Score] - Reported5{score}S
1996-05-18Hemoglobin [Mass/volume] in Blood14.2g/dL13.5-17.5 g/dLNormalS
1996-05-18Leukocytes [#/volume] in Blood by Automated count510*3/uL4-11 10*3/uLNormalS
1996-05-18Platelets [#/volume] in Blood by Automated count12910*3/uL150-400 10*3/uLLowS
1996-05-18Creatinine [Mass/volume] in Serum or Plasma0.89mg/dL0.74-1.35 mg/dLNormalS
1996-05-18Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1991)/1.73 sq M100mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1996-05-18Glucose [Mass/volume] in Serum or Plasma118mg/dL70-99 mg/dLHighS
1996-05-18Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-55 U/LNormalS
1996-05-18Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L8-48 U/LNormalS
1996-05-18Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
1996-05-18Albumin [Mass/volume] in Serum or Plasma3.9g/dL3.5-5 g/dLNormalS
1996-05-18Calcium [Mass/volume] in Serum or Plasma9.3mg/dL8.6-10.3 mg/dLNormalS
1996-05-18Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection0[IU]/mLNot detected is reported as 0; lower limit of quantification 15 IU/mLNormalS
1996-05-18Hemoglobin A1c/Hemoglobin.total in Blood6.4%Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosisHighS
1996-05-18Glucose management indicator6.9%Individual goal below 7%NormalS
1996-05-1825-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
1996-05-18Parathyrin.intact [Mass/volume] in Serum or Plasma48pg/mL15-65 pg/mLNormalS
1996-05-18Testosterone [Mass/volume] in Serum or Plasma455ng/dL264-916 ng/dLNormalS
1996-05-18Total score [AUDIT-C]0{score}S
1996-05-18Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1996-05-18Pain severity - 0-10 verbal numeric rating [Score] - Reported4{score}S
1996-08-17Hemoglobin [Mass/volume] in Blood14.4g/dL13.5-17.5 g/dLNormalS
1996-08-17Leukocytes [#/volume] in Blood by Automated count5.210*3/uL4-11 10*3/uLNormalS
1996-08-17Platelets [#/volume] in Blood by Automated count13410*3/uL150-400 10*3/uLLowS
1996-08-17Creatinine [Mass/volume] in Serum or Plasma0.88mg/dL0.74-1.35 mg/dLNormalS
1996-08-17Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1991)/1.73 sq M100mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1996-08-17Glucose [Mass/volume] in Serum or Plasma112mg/dL70-99 mg/dLHighS
1996-08-17Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L7-55 U/LNormalS
1996-08-17Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L8-48 U/LNormalS
1996-08-17Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma92U/L40-129 U/LNormalS
1996-08-17Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.1-1.2 mg/dLNormalS
1996-08-17Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
1996-08-17INR in Platelet poor plasma by Coagulation assay1{INR}0.9-1.1NormalS
1996-08-17Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection0[IU]/mLNot detected is reported as 0; lower limit of quantification 15 IU/mLNormalS
1996-08-17Alpha-1-Fetoprotein [Mass/volume] in Serum or Plasma3.4ng/mL<=8.3 ng/mLNormalS
1996-08-17Hemoglobin A1c/Hemoglobin.total in Blood6.3%Below 5.7% is normal; individual goal below 7%; may read falsely low in cirrhosisHighS
1996-08-17Glucose management indicator6.8%Individual goal below 7%NormalS
1996-08-17Total score [AUDIT-C]0{score}S
1996-08-17Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1996-08-17Pain severity - 0-10 verbal numeric rating [Score] - Reported4{score}S
1996-09-21Cholesterol [Mass/volume] in Serum or Plasma148mg/dL<=199 mg/dLNormalS
1996-09-21Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation68mg/dLGoal below 100 mg/dL in diabetes, below 70 if higher riskNormalS
1996-09-21Cholesterol in HDL [Mass/volume] in Serum or Plasma42mg/dL>=40 mg/dLNormalS
1996-09-21Triglyceride [Mass/volume] in Serum or Plasma140mg/dL<=149 mg/dLNormalS
1996-09-21Prostate specific Ag [Mass/volume] in Serum or Plasma1.3ng/mL<=4 ng/mLNormalS
1996-09-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1996-01-12Body height178cmS
1996-01-12Body weight86kgS
1996-01-12Body mass index (BMI) [Ratio]27.1kg/m2S
1996-01-12Systolic blood pressure138mm[Hg]S
1996-01-12Diastolic blood pressure84mm[Hg]S
1996-01-12Heart rate80/minS
1996-01-12Respiratory rate14/minS
1996-01-12Body temperature36.6CelS
1996-01-12Oxygen saturation in Arterial blood by Pulse oximetry98%S
1996-01-26Body height178cmS
1996-01-26Body weight85.6kgS
1996-01-26Body mass index (BMI) [Ratio]27kg/m2S
1996-01-26Systolic blood pressure136mm[Hg]S
1996-01-26Diastolic blood pressure82mm[Hg]S
1996-01-26Heart rate78/minS
1996-01-26Respiratory rate14/minS
1996-01-26Body temperature36.7CelS
1996-01-26Oxygen saturation in Arterial blood by Pulse oximetry98%S
1996-02-23Body height178cmS
1996-02-23Body weight84.8kgS
1996-02-23Body mass index (BMI) [Ratio]26.8kg/m2S
1996-02-23Systolic blood pressure128mm[Hg]S
1996-02-23Diastolic blood pressure78mm[Hg]S
1996-02-23Heart rate68/minS
1996-02-23Respiratory rate14/minS
1996-02-23Body temperature36.6CelS
1996-02-23Oxygen saturation in Arterial blood by Pulse oximetry98%S
1996-05-18Body height178cmS
1996-05-18Body weight83.2kgS
1996-05-18Body mass index (BMI) [Ratio]26.3kg/m2S
1996-05-18Systolic blood pressure118mm[Hg]S
1996-05-18Diastolic blood pressure72mm[Hg]S
1996-05-18Heart rate62/minS
1996-05-18Respiratory rate14/minS
1996-05-18Body temperature36.5CelS
1996-05-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
1996-08-17Body height178cmS
1996-08-17Body weight82.6kgS
1996-08-17Body mass index (BMI) [Ratio]26.1kg/m2S
1996-08-17Systolic blood pressure120mm[Hg]S
1996-08-17Diastolic blood pressure74mm[Hg]S
1996-08-17Heart rate60/minS
1996-08-17Respiratory rate14/minS
1996-08-17Body temperature36.6CelS
1996-08-17Oxygen saturation in Arterial blood by Pulse oximetry98%S
1996-09-21Body height178cmS
1996-09-21Body weight82.4kgS
1996-09-21Body mass index (BMI) [Ratio]26kg/m2S
1996-09-21Systolic blood pressure122mm[Hg]S
1996-09-21Diastolic blood pressure74mm[Hg]S
1996-09-21Heart rate62/minS
1996-09-21Respiratory rate14/minS
1996-09-21Body temperature36.6CelS
1996-09-21Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1996-01-12New patient: chronic pain from old fractures, diabetes, and raised liver tests with low platelets on today's tests: hepatitis C and liver work-up, NSAIDs stopped, alcohol counseling, and hepatology review bookedfinishedS
1996-01-26Hepatitis C confirmed with compensated cirrhosis: elastography, hepatology consultation, carvedilol for portal hypertension, statin, vaccines, and the antiviral planfinishedS
1996-02-23Day 1 of sofosbuvir-velpatasvir: drug interaction check, carvedilol titration, glucose monitoring, vitamin D, and the bone density planfinishedS
1996-05-18End of 12 weeks of antiviral treatment: liver tests, glucose monitoring in cirrhosis, osteoporosis, pain, and abstinencefinishedS
1996-08-17Cure confirmed (SVR12): six-month liver cancer surveillance, cirrhosis care after cure, and transplant criteria reviewedfinishedS
1996-09-21Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Hepatology consultation within three weeks to confirm and stage chronic liver disease and plan antiviral treatment if hepatitis C is confirmedcompletedGL-AASLD-HCV-2026, GL-AASLD-HCC-2023S
Liver work-up for raised transaminases and low platelets: hepatitis C antibody with reflex RNA, hepatitis B surface antigen, core antibody and surface antibody, hepatitis A IgG, HIV, INR, ultrasound of the abdomen, and FIB-4 from today's testscompletedGL-AASLD-HCV-2026, GL-USPSTF-HCV-2020S
Pain care safe in liver disease: stop ibuprofen and omeprazole; acetaminophen up to 2 g a day; topical diclofenac for the knees; no opioids; physical and aquatic therapy; heat, pacing and sleep routines; pain coping skillscompletedGL-RAKOSKI-2018, GL-CDC-OPIOID-2022S
Alcohol: brief counseling toward stopping completely, because alcohol speeds liver scarring; follow-up AUDIT-C at each visit; counseling or medicine for alcohol use offered if he cannot stopcompletedGL-USPSTF-ALC-2018, GL-AASLD-ALD-2019S
Sofosbuvir-velpatasvir one tablet daily for 12 weeks under the AASLD-IDSA simplified pathway for compensated cirrhosis, after hepatitis B testing and a drug interaction check (no proton pump inhibitor; watch for muscle pain on atorvastatin); glucose monitoring for hypoglycemia; HCV RNA and liver tests 12 or more weeks after the last dosecompletedGL-AASLD-HCV-2026, GL-AASLD-HCV-MON, GL-EPCLUSA-LABELS
Carvedilol for clinically significant portal hypertension (liver stiffness 25 kPa or more), started at 6.25 mg and raised to 12.5 mg daily if blood pressure allows; no screening endoscopy while he takes it; liver stiffness and platelets rechecked a year after curecompletedGL-BAVENO-VII-2022, GL-AASLD-PH-2024S
Liver cancer surveillance by ultrasound with alpha-fetoprotein every six months, continuing after cure because cirrhosis remainscompletedGL-AASLD-HCC-2023, GL-AASLD-HCV-2026S
Vaccines for chronic liver disease: hepatitis A (two doses) and hepatitis B (two doses), then influenza, pneumococcal and zoster vaccines at the preventive visitcompletedGL-CDC-IMZ-2026, GL-AASLD-HCV-2026S
Teaching on decompensation (swelling of the abdomen or legs, black stools or vomiting blood, confusion, yellow eyes) with same-day contact; transplant referral only if decompensation occurs or the MELD-Na reaches 15completedGL-AASLD-ASCITES-2021, GL-AASLD-PH-2024S
Diabetes care adapted to cirrhosis: metformin continued while kidney function is normal and he does not drink; continuous glucose monitoring because the A1c can read falsely low; moderate-intensity statin; yearly eye and foot examinations and urine albumincompletedGL-ADA-4-2026, GL-ADA-6-2026, GL-CMID-2026S
Falls and fractures: physical therapy and a home safety review; vitamin D; bone density scan, since cirrhosis, alcohol and many old fractures raise the risk of osteoporosiscompletedGL-ENDO-OSTEO-MEN-2012, GL-CMID-2026S
Zoledronic acid 5 mg intravenously once a year, after vitamin D repletion and a normal calcium, rather than an oral bisphosphonate because of portal hypertension; dental review first; bone density again in two yearscompletedGL-ENDO-OSTEO-MEN-2012, GL-CMID-2026S
Depression and distress screening at each visit, and plain explanations with written informationcompletedGL-USPSTF-DEP-2023, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Hepatitis C confirmed or excluded and liver disease staged within three weeks1996-01-26completedChronic hepatitis C, genotype 1a, with compensated cirrhosis staged at two weeksS
Cure of hepatitis C: HCV RNA not detected 12 or more weeks after treatment1996-08-17completedHCV RNA not detected 13 weeks after a 12-week courseS
No decompensation (ascites, variceal bleeding, encephalopathy or jaundice); Child-Pugh A and MELD-Na below 151996-08-17completedNo decompensation; Child-Pugh A5; MELD-Na 6 after cureS
No alcohol1996-08-17completedNo alcohol since the start of antiviral treatment; AUDIT-C 0S
Pain 4 of 10 or less, walking 30 minutes, with no oral NSAIDs or opioids1996-08-17completedPain 4 of 10; walking 30 minutes in the pool and on flat ground; no NSAIDs or opioidsS
Glucose management indicator below 7% without hypoglycemia1996-08-17completedGlucose management indicator 6.8%; no hypoglycemiaS
Vitamin D replete and osteoporosis treatment started; no falls with injury1996-08-17completedVitamin D 34 ng/mL; zoledronic acid given; no further fallsS

Functional Status

Mental Status